The development of HOPO Therapeutics’ lead drug candidate as a medical countermeasure for use in a radiological disaster scenario is detailed in an interview with co-founder Rebecca Abergel, Ph.D. in Cancer Cytopathology , a journal of the American Cancer Society . An effective treatment for removal of radioactive and other heavy metals from the body, its performance in preclinical trials has been vastly superior to any other chelating agent.
